JP5452925B2 - Pgds阻害剤としてのピリミジンアミド化合物 - Google Patents

Pgds阻害剤としてのピリミジンアミド化合物 Download PDF

Info

Publication number
JP5452925B2
JP5452925B2 JP2008534664A JP2008534664A JP5452925B2 JP 5452925 B2 JP5452925 B2 JP 5452925B2 JP 2008534664 A JP2008534664 A JP 2008534664A JP 2008534664 A JP2008534664 A JP 2008534664A JP 5452925 B2 JP5452925 B2 JP 5452925B2
Authority
JP
Japan
Prior art keywords
phenyl
pyrimidine
carboxylic acid
benzylamide
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008534664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510170A (ja
JP2009510170A5 (enExample
Inventor
スーザン・シー・アルダス
ジョン・ジキ・ジアーン
ジンキ・ルー
リアーン・マー
ラン・ムー
ハリー・ランドル・マンソン
ジェフリー・スティーヴン・サボール
スカンティニ・トゥライラトナム
クリストファー・ローレン・ヴァンドューセン
Original Assignee
アベンティス・ファーマスーティカルズ・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベンティス・ファーマスーティカルズ・インコーポレイテツド filed Critical アベンティス・ファーマスーティカルズ・インコーポレイテツド
Publication of JP2009510170A publication Critical patent/JP2009510170A/ja
Publication of JP2009510170A5 publication Critical patent/JP2009510170A5/ja
Application granted granted Critical
Publication of JP5452925B2 publication Critical patent/JP5452925B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008534664A 2005-10-04 2006-10-04 Pgds阻害剤としてのピリミジンアミド化合物 Active JP5452925B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04
US60/723,570 2005-10-04
PCT/US2006/038841 WO2007041634A1 (en) 2005-10-04 2006-10-04 Pyrimidine amide compounds as pgds inhibitors

Publications (3)

Publication Number Publication Date
JP2009510170A JP2009510170A (ja) 2009-03-12
JP2009510170A5 JP2009510170A5 (enExample) 2009-11-19
JP5452925B2 true JP5452925B2 (ja) 2014-03-26

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008534664A Active JP5452925B2 (ja) 2005-10-04 2006-10-04 Pgds阻害剤としてのピリミジンアミド化合物

Country Status (27)

Country Link
US (1) US8202863B2 (enExample)
EP (1) EP1937652B1 (enExample)
JP (1) JP5452925B2 (enExample)
KR (1) KR101457966B1 (enExample)
CN (2) CN101538246B (enExample)
AR (1) AR056871A1 (enExample)
AU (1) AU2006299428B2 (enExample)
BR (1) BRPI0616815A2 (enExample)
CA (1) CA2624749C (enExample)
CR (1) CR9832A (enExample)
DO (1) DOP2006000210A (enExample)
EC (1) ECSP088335A (enExample)
ES (1) ES2514471T3 (enExample)
IL (1) IL190411A (enExample)
MA (1) MA29925B1 (enExample)
MY (1) MY151172A (enExample)
NO (1) NO20082000L (enExample)
NZ (1) NZ567208A (enExample)
PE (2) PE20110118A1 (enExample)
RU (1) RU2420519C2 (enExample)
SG (1) SG166121A1 (enExample)
TN (1) TNSN08104A1 (enExample)
TW (1) TWI415839B (enExample)
UA (1) UA93213C2 (enExample)
UY (1) UY29840A1 (enExample)
WO (1) WO2007041634A1 (enExample)
ZA (1) ZA200802222B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200802411B (en) * 2005-09-15 2009-09-30 Orchid Res Lab Ltd Novel pyrimidine carboxamides
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
KR20080109918A (ko) 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2010519328A (ja) * 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンd2が媒介する疾患の治療のためのそれらの使用
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
MX2010003865A (es) 2007-10-11 2010-06-01 Vertex Pharma Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
NZ584475A (en) * 2007-10-11 2012-07-27 Vertex Pharma Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
RU2010118481A (ru) 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов
US8153651B2 (en) * 2007-11-13 2012-04-10 Evotec Ag Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8188280B2 (en) * 2008-02-06 2012-05-29 Msd K.K. 3-substituted sulfonyl piperidine derivative
EP2286221A4 (en) * 2008-05-13 2011-07-06 Cayman Chem Co METHOD FOR TESTING COMPOUNDS OR MEANS FOR THEIR POSSIBILITY TO DISPLACE STRONG LIGANDS OF THE HEMATOPOIETIC PROSTAGLANDIN D-SYNTHASE
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
JP5111657B2 (ja) 2009-03-09 2013-01-09 大鵬薬品工業株式会社 プロスタグランジンd合成酵素を阻害するピペラジン化合物
MX2012003021A (es) * 2009-10-08 2012-04-10 Sanofi Sa Derivados de feniloxadiazol como agentes inhibidores de las pgds.
AU2011208139B2 (en) 2010-01-22 2014-10-23 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a PGDS inhibitory effect
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
WO2011150457A2 (en) * 2010-06-01 2011-12-08 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
AU2011299904A1 (en) 2010-09-07 2013-05-02 Taiho Pharmaceutical Co., Ltd. Prostaglandin D synthase inhibitory piperidine compounds
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
CN104159587A (zh) 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
RU2655914C9 (ru) * 2012-08-24 2018-07-24 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах
WO2017103851A1 (en) 2015-12-17 2017-06-22 Astex Therapeutics Limited Quinoline-3-carboxamides as h-pgds inhibitors
WO2017160832A1 (en) * 2016-03-14 2017-09-21 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US11149035B2 (en) 2017-06-13 2021-10-19 Glaxosmithkline Intellectual Property Dfvelopment Limited Chemical compounds as H—PGDS inhibitors
EP3700521B1 (en) * 2017-10-29 2024-06-12 China Medical University Use of adam9 inhibitor compound and composition including adam9 inhibitor compound
CN111479814A (zh) 2017-12-13 2020-07-31 葛兰素史密斯克莱知识产权发展有限公司 作为h-pgds抑制剂的稠合的吡啶
CA3093050A1 (en) * 2018-03-23 2019-09-26 Step Pharma S.A.S. Aminopyrimidine derivatives as ctps1 inhibitors
WO2020095215A1 (en) 2018-11-08 2020-05-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
AU2021272972A1 (en) * 2020-05-13 2022-12-08 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
EP4169575A4 (en) 2020-06-19 2023-10-25 Sato Pharmaceutical Co., Ltd. Condensed ring compounds that inhibit h-pgds
EP4232425A4 (en) * 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
AU2022394333A1 (en) 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
KR20240121786A (ko) 2021-12-17 2024-08-09 사토 세이야쿠 가부시키가이샤 H-pgds를 저해하는 아자인돌 유도체

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
WO2004011430A1 (ja) * 2002-07-25 2004-02-05 Yamanouchi Pharmaceutical Co., Ltd. ナトリウムチャネル阻害剤
CA2494102A1 (en) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
ES2337254T3 (es) * 2003-02-14 2010-04-22 Glaxo Group Limited Derivados de carboxamida.
DE60303238T2 (de) * 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
US7338950B2 (en) * 2003-10-07 2008-03-04 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
EP1737414A2 (en) * 2004-01-23 2007-01-03 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
PE20070589A1 (es) 2007-06-22
IL190411A (en) 2013-09-30
MA29925B1 (fr) 2008-11-03
WO2007041634A1 (en) 2007-04-12
BRPI0616815A2 (pt) 2011-07-05
AU2006299428B2 (en) 2012-04-26
MY151172A (en) 2014-04-30
UA93213C2 (en) 2011-01-25
ZA200802222B (en) 2009-09-30
NO20082000L (no) 2008-06-09
CN101538246A (zh) 2009-09-23
CN101282943A (zh) 2008-10-08
SG166121A1 (en) 2010-11-29
EP1937652A1 (en) 2008-07-02
CA2624749A1 (en) 2007-04-12
EP1937652B1 (en) 2014-07-30
US8202863B2 (en) 2012-06-19
TNSN08104A1 (en) 2009-07-14
RU2008117170A (ru) 2009-11-10
TWI415839B (zh) 2013-11-21
KR101457966B1 (ko) 2014-11-04
AU2006299428A1 (en) 2007-04-12
JP2009510170A (ja) 2009-03-12
CA2624749C (en) 2011-08-16
AR056871A1 (es) 2007-10-31
KR20080050611A (ko) 2008-06-09
NZ567208A (en) 2011-03-31
CN101538246B (zh) 2014-07-16
RU2420519C2 (ru) 2011-06-10
ECSP088335A (es) 2008-05-30
ES2514471T3 (es) 2014-10-28
CR9832A (es) 2008-06-18
TW200812977A (en) 2008-03-16
PE20110118A1 (es) 2011-03-08
IL190411A0 (en) 2008-11-03
DOP2006000210A (es) 2007-06-15
US20080227782A1 (en) 2008-09-18
UY29840A1 (es) 2007-05-31

Similar Documents

Publication Publication Date Title
JP5452925B2 (ja) Pgds阻害剤としてのピリミジンアミド化合物
JP5427769B2 (ja) Pgds阻害剤としてのピリミジンヒドラジド化合物
CN101039920B (zh) 作为前列腺素d2受体拮抗剂的2,6-取代的-4-单取代的氨基嘧啶
JP2002308875A (ja) エンドセリンの活性を調節するスルホンアミドおよびそれらの誘導体
AU2008348817B2 (en) Beta-amino acid derivatives for treatment of diabetes
KR101701135B1 (ko) Pgds 억제제로서의 페닐옥사디아졸 유도체
CN102395584A (zh) 用于代谢疾病治疗的化合物
TW201200133A (en) Substituted pyrimidines as prostaglandin D2 receptor antagonists
TW201522330A (zh) 2-醯胺噻唑衍生物或其鹽
KR20100122944A (ko) 당뇨병 타입 1 및 2를 치료 및 예방하기 위한 5-옥소-2,3,4,5-테트라하이드로-벤조[b]옥세핀-4-카르복실산 아미드 및 2,3-디하이드로-벤조[b]옥세핀-4-카르복실산 아미드
JP3012338B2 (ja) アリールおよびヘテロアリールアルコキシナフタレン誘導体
HK1136162A (en) Pyrimidine amide compounds as pgds inhibitors
HK1139413A (en) Pyrimidine hydrazide compounds as pgds inhibitors
CN1972927A (zh) 用于治疗血脂障碍的化合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091002

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120815

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130712

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140106

R150 Certificate of patent or registration of utility model

Ref document number: 5452925

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250